title: Posaconazole for the treatment of mucormycosis.
abstract: Posaconazole (PCZ) is an orally administered, extended-spectrum triazole antifungal agent with activity against the Mucorales. This article describes the clinical and laboratory data supporting its use against this rare group of pathogens. To date, PCZ has been mostly used for salvage therapy and at present there is no strong published clinical evidence to support its role as a single agent in the treatment of mucormycosis. Further studies are required to explore its role as a single agent and in combination therapy for the management of these infections.
authors.affiliation: Clinical Microbiology & Public Health Laboratory, Peterborough & Stamford Hospitals NHS Foundation Trust, Peterborough City Hospital, Bretton Gate, Peterborough PE3 9GW, UK. david.enoch@pbh-tr.nhs.uk
authors.forename: D A
authors.initials: DA
authors.lastname: Enoch
authors.forename: S H
authors.initials: SH
authors.lastname: Aliyu
authors.forename: O
authors.initials: O
authors.lastname: Sule
authors.forename: S J
authors.initials: SJ
authors.lastname: Lewis
authors.forename: J A
authors.initials: JA
authors.lastname: Karas
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009090:Mucorales / Q000187:drug effects; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole